{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-008412","form_type":"8-K","ticker":"BBLG","cik":"0001419554","company_name":"Bone Biologics Corp","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.132476+00:00","generated_at":"2026-06-05T05:24:16.449514+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia","bullets":["NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.","Three Australian hospital sites engaged after HREC approval; study design reviewed by FDA.","Inclusion: DDD at one level L2-S1, up to Grade 1 spondylolisthesis or retrolisthesis.","Progress supports advancement toward potential US pivotal trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-008412","json":"https://secwatch.observer/filing/0001493152-24-008412.json","markdown":"https://secwatch.observer/filing/0001493152-24-008412.md","text":"https://secwatch.observer/filing/0001493152-24-008412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/0001493152-24-008412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:24:16.449514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}